30/06/2016 13:37:17 1-888-992-3836 (toll free) Free Membership Login

Myriad Genetics News (NASDAQ:MYGN)

DateTimeSource
Headline
06/29/20167:15AMGLOBEMyriad’s myChoice® HRD Test Successfully Identifies Patients that Meet Primary Endpoint in TESARO’s Pivotal Phase 3 Ovar...
SALT LAKE CITY, June 29, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that its myChoice® HRD test successfully identified an increased number of patients with ovarian cancer who may benefit from treatment with niraparib. ... More...>>
06/17/20168:20AMPRNUSActive Equities to Watch in the Services Sector -- Booz Allen Hamilton Holding, Qiagen, INC Research Holdings, and Myriad Gen...
Active Equities to Watch in the Services Sector -- Booz Allen Hamilton Holding, Qiagen, INC Research Holdings, and Myriad Genetics PR Newswire NEW YORK, June 17, 2016 NEW YORK, June 17, 2016 /PRNewswire/ -- On Thursday, June 16, 2016, the NASDAQ Composite ended the trading session at 4,844.92, up 0.21%; the Dow Jones Industrial... More...>>
06/10/20167:05AMGLOBECrescendo Bioscience Announces that New Data on Vectra® DA Will Be Presented at the European League Against Rheumatism 17th ...
SALT LAKE CITY, June 10, 2016 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that new data on the use of Vectra® DA test to predict treatment response in patients with rheumatoid arthritis (RA) are being presented at European League Against Rheumatism... More...>>
06/07/20167:05AMGLOBEMyriad Board Approves $200 Million Increase in Share Repurchase Program
SALT LAKE CITY, June 07, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that its board of directors has approved an additional $200 million authorization for its share repurchase program. As of the end of the third quarter of fiscal year 2016, the Company had repurchased greater than $1.1... More...>>
06/06/20167:05AMGLOBEMyriad myRisk® Hereditary Cancer Test Demonstrates the Magnitude of Breast and Ovarian Cancer Risk in Nearly 100,000 Patien...
SALT LAKE CITY, June 06, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that two analyses demonstrating the utility of the Myriad myRisk® Hereditary Cancer test will be featured in oral presentations at the 2016 American Society... More...>>
06/06/20167:05AMGLOBEMyriad Genetics to Present at the 2016 Goldman Sachs Healthcare Conference
SALT LAKE CITY, June 06, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) announced today that Mark C. Capone, president and CEO, is scheduled to present at the Goldman Sachs Healthcare Conference at 10:00 a.m. Pacific on June 8, 2016, at the Terranea Resort in Rancho Palos Verdes, California. The presentation... More...>>
06/05/20167:05AMGLOBEMyriad Will Present Three New Hereditary Cancer Studies at the ASCO Annual Meeting
SALT LAKE CITY, June 05, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that results from three studies with the Myriad myRisk® Hereditary Cancer test will be featured in podium presentations at the 2016 American Society of Clinical... More...>>
05/31/20164:05PMONEMyriad Acquires Sividon Diagnostics
Strengthens Market Leading Oncology Product Portfolio with Breast Cancer Prognostic Test EndoPredict® SALT LAKE CITY, May 31, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it has acquired Sividon Diagnostics, a leading breast... More...>>
05/31/20164:05PMGLOBEMyriad Acquires Sividon Diagnostics
SALT LAKE CITY, May 31, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it has acquired Sividon Diagnostics, a leading breast cancer prognostic company, for €35 million upfront with the potential for €15 million in additional... More...>>
05/19/20164:56PMGLOBEMyriad Genetics’ Statement on HIPAA Complaint from Four Patients
SALT LAKE CITY, May 19, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced a complaint was filed against the Company with the Department of Health and Human Services on behalf of four individuals seeking their genetic testing results. ... More...>>
05/18/20165:57PMGLOBEMyriad Announces Plans to Launch a Web Portal for Patients that Will Provide Access to Test Results, Tools and Health Informa...
SALT LAKE CITY, May 18, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced plans to launch a new web portal on ms360.myriad.com that will allow patients to access their personal test results as well as other high-quality tools and ideas... More...>>
05/18/20165:05PMGLOBEMyriad to Present New Research at the 2016 ASCO Annual Meeting
SALT LAKE CITY, May 18, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced it will present data from nine clinical studies with three different products at the 2016 American Society of Clinical Oncology annual meeting to be held June 3-7, 2016 in Chicago, Ill.  Key podium presentations will... More...>>
05/11/20167:05AMGLOBECrescendo Bioscience Launches Web Portal for Patients with Rheumatoid Arthritis
myVectraTM Enables Secure Access to Vectra® DA Test Results SOUTH SAN FRANCISCO, Calif., May 11, 2016 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that it has launched a new web-based portal called myVectra for patients with rheumatoid arthritis... More...>>
05/06/20167:05AMGLOBEMyriad to Present Three New Studies at the AUA Annual Meeting
SALT LAKE CITY, May 06, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that results from three studies will be featured at the American Urological Association annual meeting, which will take place May 6-10 in San Diego, Calif. ... More...>>
05/03/20164:05PMGLOBEMyriad Genetics Reports Fiscal Third-Quarter 2016 Financial Results
Total Revenues of $190.5 Million Adjusted EPS of $0.41 and Diluted EPS of $0.44 Company Issues Fiscal Fourth-Quarter and Updates Fiscal Year 2016 Financial Guidance   SALT LAKE CITY, May 03, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced financial results for its fiscal third-quarter... More...>>
05/02/20167:05AMGLOBEMyriad Genetics to Present at the Bank of America Health Care Conference
SALT LAKE CITY, May 02, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) announced today that R. Bryan Riggsbee, chief financial officer, Myriad Genetics, is scheduled to present at the 2016 Bank of America  Healthcare Conference at 3:40 p.m. PDT (6:40 pm EDT) on May 11, 2016, at the Encore at Wynn in... More...>>
04/28/201611:46AMGLOBEMyriad to Announce Fiscal Third-Quarter 2016 Financial Results on May 3
SALT LAKE CITY, April 22, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will hold its fiscal third-quarter 2016 sales and earnings conference call with investors and analysts at 4:30 p.m. ET on Tuesday, May 3.  During the call, Mark C. Capone, president and CEO and Bryan Riggsbee... More...>>
04/14/20167:05AMGLOBEMyriad Genetics Announces Presentations at the 2016 American Association for Cancer Research Annual Meeting
SALT LAKE CITY, April 14, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that the company and its scientific collaborators will present two studies at the American Association for Cancer Research annual meeting, April 16-20, in... More...>>
03/30/20167:05AMGLOBEMyriad myRisk® Hereditary Cancer Article in Journal of Clinical Oncology Highlights Importance of Expanding Genetic Testing ...
SALT LAKE CITY, March 30, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, working in collaboration with researchers from the Harvard Medical School, today announced that the Journal of Clinical Oncology has published a paper showing the frequency... More...>>
03/21/20167:05AMGLOBEMyriad Genetics Teams Up with Access Health® to Educate the Public about Hereditary Cancer and Genetic Testing
SALT LAKE CITY, March 21, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, and Access Health®, an educational program focused on health and wellness, today announced that they will air an educational program on hereditary cancer that will appear... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:32 V:us D:20160630 17:37:19